Chise Profile picture
Jul 20, 2022 14 tweets 8 min read Read on X
Just a friendly reminder. Despite what you might hear, there has yet to be a variant that isn’t susceptible to the vaccines.

Let’s stop the misinformation and look at the updated data, shall we? Yes, this includes BA.5. ⬇️🧵
Why are variants unlikely to FULLY evade vaccine-induced immunity?
•Vaccines are POLYCLONAL
•CD8+ T-cells covering 52 epitopes across the spike protein
•CD4+ T-cells covering 23 epitopes across the spike protein
science.org/doi/10.1126/sc…
I am seeing a ton of misinformation circulating so I thought it might be a good idea to make a thread on this. When you see “waning” or “evading vaccines” PLEASE KEEP IN MIND this is usually in regards to neutralizing antibodies ONLY. NOT PROTECTION AGAINST SEVERE DISEASE. ImageImageImageImage
I say this is because it is important to know while updated vaccines are expected in autumn of this year (BA.4/BA.5 targeted), our current vaccines ARE indeed STILL VERY EFFECTIVE against severe disease. PEER-REVIEWED:
nejm.org/doi/full/10.10…
thelancet.com/journals/lanre… ImageImageImageImage
NEWEST PEER-REVIEWED study. Although Omicron sublineages can evade some nAb responses elicited by primary vaccine series, vaccine boosters provide SUFFICIENT protection against Omicron-induced SEVERE disease. The study evaluates MULTIPLE vaccine types.
fcld.ly/a5ws8g1 Image
Chise, what about the preprint out of Japan regarding BA.4/BA.5 severity? AGAIN, it turns out if you read the study and look at the antigenic data, they only show an antigenic difference when they used RODENT sera. When they tested human sera, there was NO DIFFERENCE in severity.
Those are HAMSTER MODELS. BA.2 was NOT more pathogenic in humans than other VOCs, and neither are BA.4/BA.5. These preprints aren’t a great fit for social media. Hamsters aren’t necessarily valid for modeling human disease severity, which- at this point in
the pandemic mainly will be dictated by preexisting immunity, which involves MORE THAN nAbs. Look at REAL-WORLD data out of South Africa who have found NO DIFFERENCE in risk of hospitalization or severe disease for BA.4/BA.5.
businesstech.co.za/news/lifestyle…
nature.com/articles/s4159… ImageImage
Another note on vaccines. Recent data out of UKHSA VE Report hospitalization data and community study data shows that vaccine efficacy is NO DIFFERENT for BA.2 than BA.4/BA.5 suggesting vaccines still work quite well.
bit.ly/3AxusKM Image
Adding this to data from South Africa suggesting prior infection plus three doses of a vaccine series also offer significant protection against BA.4/BA.5.
medrxiv.org/content/10.110… Image
you want other real-world data, look no further than New York’s current BA.5 wave. Notice something important? Not only are both rates remaining overwhelmingly low from the BA.2 wave in January, notice the red line? Yeah, that’s VACCINATED individuals.
coronavirus.health.ny.gov/covid-19-break… ImageImage
When you see tweets that may have absolutely NO sources or scientific data claiming BA.5 is a “beast.” PLEASE look at the real-world data. Look at the studies. I’ll be providing links but I implore you to first please read this thread.
Image
So, yes, while sublineages like these should be monitored by those WHOSE JOB IT IS TO DO SO, the general population shouldn’t panic, make sure you are boosted, and should for all intended purposes realize THESE ARE INDEED STILL OMICRON.
TLDR. Stay calm. Stay vigilant. Know your facts. YES, take the same precautions you have been. Make sure you are protected. COVID-19 vaccination remains THE key intervention against severe disease, hospitalization, Long COVID, AND death from ALL known SARS-COV-2 variants.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Chise

Chise Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @sailorrooscout

Oct 28, 2024
THIS IS HUGE! An HIV PrEP drug candidate in the form of a twice-yearly subcutaneous injection has been shown to reduce HIV infections by 96% in a SECOND late-stage Phase III trial. Lenacapavir was 99.9% effective at preventing HIV in MORE THAN 2,000 participants.🧵⬇️
These results come from the PURPOSE 2 trial evaluating Gilead Sciences’ twice-yearly, subcutaneous Lenacapavir in individuals aged 16 years or older. Lenacapavir, which is a capsid inhibitor, is already approved by the FDA under the brand name Sunlenca for use alongside other
Read 13 tweets
Oct 24, 2024
So, not COVID related BUT, this is REALLY exciting news. Phase I/II data shows Moderna’s Norovirus vaccine candidate mRNA-1403, has shown early signs of efficacy AND elicited robust serum HBGA-blocking antibody responses against ALL THREE NoV genotypes. Let’s talk about that!🧵⬇️
At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II, randomized, observer-blind, placebo-controlled, dose-ranging trial (NCT05992935) for mRNA-1403, a prophylactic vaccine candidate under investigation for norovirus (NoV) infections.
As one of the leading causes of acute gastroenteritis worldwide, NoV is associated with a substantial healthcare burden. Symptoms include vomiting and diarrhoea, which can be severely dehydrating, and the risk of severe outcomes from NoV is greatest in young children and older
Read 16 tweets
Oct 21, 2024
THIS IS HUGE! Researchers at JHU have developed an experimental drug called RK-33, that in preclinical studies has shown promise in treating breast cancer with bone metastases. RK-33 eliminated the metastases AND prevented further cancer spread. Let’s talk about that!🧵⬇️
The research has been published in Cancer Letters. Yes, it is PEER-REVIEWED.
sciencedirect.com/science/articl…Key Takeaways:  •RK-33 targets DDX3, an RNA helicase elevated in cancer cells, to inhibit breast cancer bone metastasis.  •In mouse models, RK-33 eliminated bone metastases and prevented further cancer spread without significant adverse effects.  •The study suggests RK-33 as a promising treatment for breast cancer bone metastasis, urging further research into its broader applications.
In a new study led by Johns Hopkins Medicine, the drug RK-33 has demonstrated promise in treating breast cancer that has spread to the bone (breast cancer bone metastasis). RK-33 was previously shown to help treat other types of cancer and viral illnesses.
Read 14 tweets
Oct 17, 2024
THIS IS HUGE! Researchers at Lancaster University have developed RI-AG03, a peptide inhibitor, that in preclinical studies PREVENTED the build-up of harmful Tau proteins in the brain, which are believed to be a key driver of Alzheimer’s disease. Let’s talk about that! 🧵⬇️
The research has been published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. Yes, it is PEER-REVIEWED.
•~ alz-journals.onlinelibrary.wiley.com/doi/10.1002/al…What You Need to Know ⬇️  •Scientists have developed a new drug that targets two key regions of the tau protein, a major contributor to Alzheimer’s disease.  •The drug, a peptide inhibitor called RI-AG03, successfully prevented the build-up of toxic tau proteins in both laboratory and fruit fly studies.  •Although further research is necessary, including clinical trials in humans, this research contributes to the advancement of more effective therapies for neurodegenerative diseases.  •There are two main “hotspots” on the tau protein, where fibril clumping occurs. In this new study, research...
Tau proteins are essential for maintaining the structure and function of neurons. However, in Alzheimer’s disease, these proteins malfunction and aggregate into long, twisted fibrils. As these fibrils build up, they form neurofibrillary tangles- masses of tangled tau proteins
Read 15 tweets
Oct 9, 2024
THIS IS HUGE! Researchers at the University of Pennsylvania have developed a vaccine against the bacterium Clostridioides difficile (C.diff), that in preclinical studies, protected against succumbing from infection AND prevented recurring cases. Let’s talk about that! 🧵⬇️
The study has been published in Science. Yes, it is PEER-REVIEWED.
science.org/doi/10.1126/sc…Model figure. (A) C. difficile toxins target the intestinal epithelium and cause severe pathology and gastrointestinal disease leading to morbidity and mortality. (B) When vaccinated mice are infected with C. difficile, anti-toxin IgG and IgA protect mice from disease and inclusion of PPEP-1 and CdeM as immunogens improves decolonization of toxigenic C. difficile from the gastrointestinal tract. Credit: Science (2024). DOI: 10.1126/science.adn4955
The bacterium Clostridioides difficile is named “difficult” for a reason. Originally, it was hard to grow in the lab, and, now, it’s the source of gut infections that are tough to treat. About half a million people in the U.S. contract C. diff every year, often from hospitals-
Read 15 tweets
Oct 5, 2024
THIS IS HUGE! Scientists at the University of Oxford are developing the world's FIRST ovarian cancer vaccine that could potentially wipe the disease out. OvarianVax teaches the immune system to recognize and attack the earliest stages of ovarian cancer. Let’s talk about that!🧵⬇️
The hope is that individuals could receive the vaccine preventatively with the goal of eradicating the disease. Researchers have suggested it could work in a similar way to the human papillomavirus (HPV) vaccine, which is on track to stamp out cervical cancer.
Oxford researchers are designing OvarianVax, a vaccine which teaches the immune system to recognize and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 for the study over the next three years to support lab research into the vaccine.
Read 12 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(